VELARU MANDATE EXHIBIT PACK — GXP / FDA 21 CFR PART 11 PHARMA
Jurisdiction: Brazil (br)
Modality: Text / Chat
Program: Velaru GxP / FDA 21 CFR Part 11 Pharma · Brazil (galactic_gxp_br)
Product ID: gxp:br:bundle:text
Vertical: gxp
Generated: 2026-08-22T18:33:52.246689Z
Authority: Brazil LGPD ADM Pack — GxP Electronic Records Integrity Pack
Deadline: LGPD automated decisions + ANPD AI
Velaru verify: https://velaru.xyz/verify

EXHIBIT A — AI INVENTORY
[
  {
    "named_entity": "Velari",
    "slug": "velari",
    "ai_use_case": "AI-assisted GxP / FDA 21 CFR Part 11 Pharma decisions",
    "vertical": "gxp",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/4c58eac890bfd031ce2189de5a1ca9ea292a0c837f5f535daf164aef34f31e53",
    "compliance_state": "non_compliant",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.xyz/bundle/pre-dispute/d8fb129c0c0c78d05256/export.txt",
    "diligence_url": "https://velaru.xyz/diligence/velari"
  },
  {
    "named_entity": "LinkAudit Test",
    "slug": "linkaudit-test",
    "ai_use_case": "AI-assisted GxP / FDA 21 CFR Part 11 Pharma decisions",
    "vertical": "gxp",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/58ddedd1974156453bc55daef6a9857d8570d56388becbb2a80bf5bac76b771b",
    "compliance_state": "non_compliant",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.xyz/bundle/pre-dispute/78aa6e3f3a84cf1a88c0/export.txt",
    "diligence_url": "https://velaru.xyz/diligence/linkaudit-test"
  },
  {
    "named_entity": "Link Audit Co",
    "slug": "link-audit-co",
    "ai_use_case": "AI-assisted GxP / FDA 21 CFR Part 11 Pharma decisions",
    "vertical": "gxp",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/d00533b7b6c0495802b4250abd5c29f60bd9f2ad3fb141bba2d9a5afee5f5542",
    "compliance_state": "non_compliant",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.xyz/bundle/pre-dispute/fea572f3996c4b963779/export.txt",
    "diligence_url": "https://velaru.xyz/diligence/link-audit-co"
  }
]

EXHIBIT B — GOVERNANCE FRAMEWORK
{
  "framework": "Velaru Mandate Registry \u2014 GxP / FDA 21 CFR Part 11 Pharma",
  "exhibit_authority": "Brazil LGPD ADM Pack \u2014 GxP Electronic Records Integrity Pack",
  "regulatory_frameworks": [
    "FDA 21 CFR Part 11",
    "FDA 21 CFR Part 211 GMP",
    "ICH E6 GCP",
    "ICH Q10 Pharmaceutical Quality System",
    "EU GMP Annex 11",
    "WHO GMP guidelines",
    "FDA 483 observation risk",
    "LGPD Art 20",
    "ANPD AI resolution",
    "CVM AI guidance",
    "Marco Civil"
  ],
  "standards_alignment": [
    "POSS-2",
    "DRP-1",
    "TCB",
    "FRE 707 pre-compliance",
    "ISO 42001"
  ],
  "human_oversight": "release manufacturing batch",
  "third_party_verification": "https://velaru.xyz/verify (operator-independent)",
  "data_lineage": "Hash-chained Ed25519 receipts; optional RFC3161 + external anchor",
  "mirror_trap": "QA releases batch on AI recommendation without hash-chained record \u2014 batch recall insurance void. \u00b7 LGPD Art 20 review of automated decisions \u2014 receipt enables review request response.",
  "chain_integrity": {
    "depth": 495,
    "invariant_holds": true
  }
}

EXHIBIT D — DATA INPUTS & VALIDATION
{
  "data_validation_method": "Cryptographic receipt per AI decision; public verify without trusting deployer, vendor, or Velaru operator",
  "bias_testing_proxy": "Asymmetry score from live chain signals",
  "model_change_control": "Policy lock registry \u2014 criteria hash frozen pre-dispute",
  "logging_retention": "90-day pre-dispute window minimum; permanent verify permalinks",
  "external_validator": "Nisaba LLC / Velaru",
  "validator_independence": "Client-side Ed25519 verify; BYOK tri-receipt optional",
  "headline_stat": "Delete audit trail before inspection = automatic consent decree pattern",
  "global_leaders_addressed": [
    "FDA",
    "Merck",
    "Lonza",
    "Waters Corporation",
    "ISPE",
    "ANPD",
    "Nubank",
    "BCB"
  ]
}

MIRROR TRAP (regulatory insight)
QA releases batch on AI recommendation without hash-chained record — batch recall insurance void. · LGPD Art 20 review of automated decisions — receipt enables review request response.

NERVE CARDS — WHY GLOBAL LEADERS CARE
[
  {
    "title": "Deviation reports",
    "body": "AI flags GMP deviation \u2014 without receipt, QA cannot prove when they knew.",
    "source": "vertical"
  },
  {
    "title": "Annex 11 EU",
    "body": "European GMP requires same integrity \u2014 global pharma needs one primitive.",
    "source": "vertical"
  },
  {
    "title": "Recall insurance",
    "body": "Insurers deny recall claims when electronic records integrity violated.",
    "source": "vertical"
  },
  {
    "title": "[Brazil] LatAm hub",
    "body": "Brazil sets pattern for LATAM \u2014 receipt architecture scales to Mexico, Colombia.",
    "source": "jurisdiction"
  },
  {
    "title": "[Brazil] Fintech",
    "body": "Nubank, Mercado Libre AI \u2014 BCB expects credit decision explainability.",
    "source": "jurisdiction"
  },
  {
    "title": "[Text / Chat] Modality hook",
    "body": "Baseline \u2014 all frameworks apply to text decisions.",
    "source": "modality"
  }
]

BOOK SUMMARY: {
  "total_insureds": 3,
  "compliant": 0,
  "grace_period": 0,
  "non_compliant": 3,
  "expired": 0,
  "not_enrolled": 0,
  "compliant_pct": 0.0
}

TAM / EXPOSURE: Every GMP facility globally · Part 11 is law today
INSURANCE LINES: Product recall, Pharma E&O

DISCLAIMER: External validation evidence pack — not legal advice, not filed rate approval.